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Abstract
Background
Colorectal cancer (CRC) survivors are known to experience various symptoms that signifi-
cantly affect their quality of life (QOL); therefore, it is important to identify clinical markers
related with CRC survivor QOL. Here we investigated the relationship between serum che-
merin levels, a newly identified proinflammatory adipokine, and QOL in CRC survivors.
Methods
A data of total of 110 CRC survivors were analysed in the study. Serum chemerin levels
were measured with an enzyme immunoassay analyser. Functional Assessment of Cancer
Therapy (FACT) scores were used as an indicator of QOL in CRC survivors.
Results
Weak but not negligible relationships were observed between serum chemerin levels and
FACT-General (G) (r = -0.22, p<0.02), FACT-Colorectal cancer (C) (r = -0.23, p<0.02) and
FACT-Fatigue (F) scores (r = -0.27, p<0.01) after adjusting for confounding factors. Both
stepwise and enter method multiple linear regression analyses confirmed that serum che-
merin levels were independently associated with FACT-G (stepwise: β = -0.15, p<0.01;
enter: β = -0.12, p = 0.02), FACT-C (stepwise: β = -0.19, p<0.01; enter; β = -0.14, p = 0.02)
and FACT-F scores (stepwise: β = -0.23, p<0.01; enter: β = -0.20, p<0.01).
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Conclusions
Our results demonstrate a weak inverse relationship between serum chemerin and CRC
survivor QOL. Although it is impossible to determine causality, our findings suggest that
serum chemerin levels may have a significant association with CRC survivor QOL. Further
prospective studies are required to confirm the clinical significance of our pilot study.
Introduction
Colorectal cancer (CRC) is one of the most common cancers worldwide [1]. The survival rate
of CRC patients has steadily improved in large part due to the increased rate of early detection
and more effective treatments [2]. CRC survivors are known to suffer from various symptoms,
including chronic bowel irritability and cancer-related fatigue that significantly affect their
quality of life (QOL) [3]. Therefore, long-term care that improves QOL in CRC survivors is
considered important. Furthermore, the identification of clinical markers and biomarkers that
allow clinicians to predict the QOL of CRC survivors are needed. Although the precise mecha-
nism is unknown, immune system alterations and increased expression of pro-inflammatory
cytokines are considered to mediate QOL decreases. In previous studies, increased cytokine
levels in cancer patients were significantly associated with non-specific chronic symptoms,
such as fatigue, cognitive changes, and depressed mood [4, 5].
Chemerin is a newly identified adipokine secreted by adipose tissue [6]. It is known to be
associated with carcinogenesis and several age-related metabolic disorders, including obesity,
metabolic syndrome, and insulin resistance (IR) [7, 8]. Although the precise role of chemerin
has not been fully elucidated, it is known to modulate immune system function and enhance
the pro-inflammatory process by stimulating the chemotaxis of dendritic cells and macro-
phages [9–11].
Because decreased QOL in CRC is considered to be associated with immune system alter-
ations and chronic systemic inflammation, it is possible that the pro-inflammatory adipokine
chemerin may be associated with QOL in CRC survivors. In the present study, we investigated
the relationship between QOL as measured by Functional Assessment of Cancer Therapy
(FACT) scores and serum chemerin levels in 110 Korean CRC survivors.
Materials and methods
Ethics statement
All subjects participated in the study voluntarily, and written informed consent was obtained
from each participant. The study complied with the Declaration of Helsinki, and the Institu-
tional Review Board of Severance Hospital approved this study.
Study participants
This study was performed as part of a clinical study designed to investigate factors related to
the heath of Korean CRC survivors. This study sample included 123 CRC survivors diagnosed
with stage 2 or 3 CRC between January 2011 and December 2013. They were all older than 20
years old and had completed all standard treatments between 6 week and 1 year before study
enrolment. The performance status of the participants was evaluated on the basis of Eastern
Cooperative Oncology Group performance scores, with total scores<1 indicating good
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performance. The study population was recruited by advertisement at the Outpatient Clinic of
the Department of General Surgery in Severance Hospital.
We excluded participants with histories of cancer in other organs and colostomies. Partici-
pants with a history of chronic diseases, including coronary artery occlusive disease, stroke,
chronic liver disease, or renal disease were not included. Patients with abnormal liver function
or kidney function were also excluded. Abnormal liver function was defined by serum aspar-
tate aminotransferase (AST) or alanine aminotransferase (ALT) concentrations >100 IU/L.
Abnormal kidney function was defined by serum creatinine concentrations >1.7 mg/dL. No
participants had physical or mental disabilities. Subjects who participated in vigorous exercise
(defined as high intensity of physical exercise or physical work performed >200min/week)
were also excluded. In addition, we excluded participants who were missing data for chemerin
levels and FACT scores. A total of 110 participants were included in the final analysis. Among
these 110 participants, 66 participants further participated in a randomized controlled trial to
assess the effects of probiotics (clinical trial number: KCT0001053). We performed our analy-
sis using baseline measurement data from 110 participants. (S1 Fig)
Measurements
Health-related questionnaires. All subjects completed a questionnaire about lifestyle
factors, including exercise, cigarette smoking, alcohol consumption, marital status, and under-
lying medical conditions. Smoking was defined as a current smoking habit, and alcohol con-
sumption was categorized into never drinking, drinking less than once a week, or drinking
alcohol once a week or more. Participants also completed a questionnaire about CRC, includ-
ing tumour location (sigmoid, ascending colon, transverse colon, descending colon, or rec-
tum), cancer stage (II or III), treatment modality (surgery, chemotherapy, radiotherapy, or
combined therapy) and intervals after treatment completion (day).
Assessment of cancer-related QOL. All subjects completed the questionnaires about can-
cer-related QOL assessed by version 4 of the FACT Measurement System [12]. Among the
FACT questionnaires, FACT-General (FACT-G), Total FACT-cancer-related (FACT-C), and
Total FACT-fatigue (FACT-F) scales were chosen in this study. A five-point Likert self-report
scale with scores ranging from 0 to 4 was used, with higher scores indicating better conditions.
The FACT-G is a 27-item questionnaire divided into 4 subcategories: physical well-being
(PWB), social well-being (SWB), emotional well-being (EWB), and functional well-being
(FWB). The range of possible scores is 0–108.
The FACT-C is a 9-item questionnaire about CRC-related QOL issues, with a range of pos-
sible scores of 0–28. The total FACT-C total scores were calculated by summation of PWV,
SWB, EWB, FWB, and Fact-C scores (score ranges 0–136).
The FACT-F is a 13-item fatigue subscale. The range of possible scores is 0–52. The total
FACT-F total scores were calculated by summation of the PWV, SWB, EWB, FWB, and Fact-F
scores (Score ranges 0–160).
Anthropometric measurements. Anthropometric measurements were taken by a single
well-trained examiner. Blood pressure (BP) was measured in the sitting position after a
10-minute resting period. Body mass index (BMI) was calculated as weight divided by height
squared. Waist circumference was measured at the umbilicus while the subject was standing.
Bioelectrical impedance analysis was used to estimate body fat percentage and lean body mass
using the InBody U20 (Biospace, Seoul, Korea).
Blood samples were collected after at least an 8-hour overnight fasting period. White blood
cell counts, fasting glucose, total cholesterol, high-density lipoprotein (HDL) cholesterol, tri-
glyceride, high sensitive C-reactive protein (hs-CRP) and gamma-glutamyl-transpeptidase
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(GGT) concentrations were measured using an ADVIA 1650 chemistry system (Siemens Med-
ical Solution, Tarrytown, NY, USA). Fasting insulin was determined by electrochemilumines-
cence immunoassay using an Elecsys 2010 (Roche, Indianapolis, IN, USA). IR was estimated
by the homeostasis model assessment of insulin resistance (HOMA-IR) index: (insulin [μIU/
mL] × fasting blood glucose [mg/dL]/18)/22.5. Serum chemerin levels were measured with an
enzyme immunoassay kit (Mesdia, Seoul, Korea), and the inter- and intra-assay variabilities
were 11.3±6.0% and 8.4±3.7%, respectively.
Statistical analysis
Normally distributed data are expressed as means±standard deviations (SD), and non-nor-
mally distributed data are expressed as medians and interquartile ranges. Non-normally dis-
tributed data were logarithmically transformed to reduce the skewness of the distribution.
Pearson correlation analysis was performed to evaluate relationships between FACT scores
and other clinical variables. To assess the association between FACT scores and serum che-
merin levels, Pearson’s partial correlation analyses were performed to determine the correla-
tions between serum chemerin levels and FACT-C, FACT-F and FACT-G scores after
adjusting for other variables with p<0.10 from simple Pearson correlation analyses and clini-
cally important variables, including age, sex, smoking and alcohol consumption. To avoid
multicollinearity, if there was significant correlation (r>0.7) between two variables, only one
variable was selected and entered into the model.
Multiple linear regression analyses with stepwise and enter methods were used to identify
factors contributing to FACT scores. For this analysis, the same variables adjusted in the Pear-
son’s partial correlation analyses were entered. For the comparison of r2 between the full
model and reduced model (null model) without chemerin, an F-test was performed.
We performed all statistical analysis using the Statistical Package for the Social Sciences,
version 18.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was defined as p<0.05.
Results
Table 1 shows the clinical characteristics of the subjects. The mean age of participants was
56.29±9.27 years, and the mean chemerin level was 104.69±14.31 ng/mL. QOL scores related
with general symptoms (FACT-G scores), CRC-related symptoms (FACT-C scores), and
fatigue-related symptoms (FACT-F scores) were 80.57±13.68, 100.89±16.53, and 122.40
±18.40, respectively.
In correlation analyses, FACT-G and FACT-C scores were negatively related with age (r =
-0.19, p = 0.04; r = -0.20, p = 0.04), fat percent (r = -0.17, p = 0.04; r = -0.17, p = 0.04), triglycer-
ide (r = -0.22, p = 0.02; r = -0.22, p = 0.02), high-sensitivity C-reactive protein (hsCRP; r =
-0.22, p = 0.02; r = -0.23, p = 0.02) and chemerin levels (r = -0.29, p<0.01; r = -0.29, p<0.01).
In addition, FACT-F scores were negatively correlated with triglyceride (r = -0.22, p = 0.02)
and chemerin levels (r = -0.31, p<0.01) (Table 2). There was also a significant correlation
between chemerin and hs-CRP levels (r = 0.48, p<0.01). The weak but significant correlations
between serum chemerin levels and FACT-G and FACT-F scores were maintained after
adjustments were made for age, sex, fat percent, smoking, alcohol use, insulin, and triglyceride
(r = -0.22, p<0.02 for FACT-G scores; r = -0.27, p<0.01 for FACT-F scores). A weak correla-
tion between serum chemerin level and FACT-C scores persisted after adjusting for age, sex,
fat percent, smoking, alcohol use, lean body mass, and triglyceride (r = -0.23, p<0.02) (Fig 1).
Finally, independent associations of QOL scores with serum chemerin levels were assessed
in multivariate-adjusted models by multiple regression analyses with the enter method. Che-
merin was identified as a significant independent variable associated with FACT-G (β = -0.12,
Serum chemerin and quality of life in colorectal cancer survivors
PLOS ONE | https://doi.org/10.1371/journal.pone.0176929 May 5, 2017 4 / 12
Table 1. Subjects’ clinical characteristics (n = 110).
Variables Mean±SD or Median (25th–75th percentile)
Age (years) 56.29±9.27
Gender (n, %)
Male 55 (50.0)
Female 55 (50.0)
Marriage (n, %) 92 (82.9)
Smoking status (n, %)
None 52 (47.3)
Current 24 (21.8)
Past 34 (30.9)
Alcohol consumption (n, %)
Never 87 (79.1)
<1/week 14 (12.7)
>1/week 9 (8.2)
Cancer location (n, %)
Colon
Sigmoid 45 (40.9)
Ascending 21 (19.1)
Transverse 6 (5.5)
Descending 5 (4.5)
Rectum 33 (30.0)
Cancer stage (n, %)
II 54 (49.1)
III 56 (50.9)
Treatment (n, %)
Surgery + Chemotherapy 101 (91.8)
Surgery + Chemo-radiotherapy 9 (8.2)
Intervals after treatment completion (day) 257.00 (113.00–418.00)
Adiposity index
BMI (kg/m2) 23.31±3.06
Waist (cm) 81.90±9.10
Lean body mass (cm2)# 25.40 (20.50–29.00)
Fat (%) 27.33±7.85
BP (mmHg)
Systolic 130.22±13.66
Diastolic 78.72±11.20
Fasting glucose (mg/dL)# 90.00(85.00–98.00)
Fasting insulin (μIU/mL)# 5.80 (3.47–8.63)
HOMA-IR# 1.31 (0.80–2.03)
Lipid profile (mg/dL)
Total cholesterol 191.13±35.17
Triglyceride# 100.5 (71.00–150.00)
HDL-cholesterol# 53.55 (46.50–62.20)
WBC count# 4570 (3800–5640)
GGT# 22.00(14.00–37.00)
Chemerin 104.69±14.31
FACT-G score 80.57±13.68
Total FACT-C score 100.89±16.53
(Continued )
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p = 0.02), FACT-C (β = -0.14, p = 0.02), and FACT-F scores (β = -0.20, p<0.01) after adjust-
ments for age, gender, smoking, alcohol use, fat percent, triglycerides, and insulin for FACT-
G, FACT-F and adjustments for age, gender, smoking, alcohol, fat percent, lean body mass,
and triglycerides for FACT-C scores. Furthermore, r2 increased significantly when comparing
between the null and full models (chemerin added) in analyses (FACT-G scores; 0.12–0.16,
p = 0.02, FACT-C scores; 0.13–0.17, p = 0.02, FACT-F scores; 0.12 to 0.18, p<0.01). These
associations remained significant in stepwise multiple regression analyses (β = -0.15, p<0.01
for FACT-G, β = -0.19, p<0.01 for FACT-C and β = -0.23, p<0.01 for FACT-F scores) after
adjustments for age, sex, BMI, alcohol consumption, smoking, marriage, cancer stage, treat-
ment modality, cancer location, intervals after treatment completion, lean body mass, systolic
BP, total cholesterol, HDL-cholesterol, triglycerides, fasting glucose, insulin, gamma glutamyl
transferase (GGT), and hs-CRP (Table 3).
Discussion
Our cross-sectional pilot study showed a weak but significant inverse relationship between
CRC-related QOL and serum chemerin levels in 111 cancer survivors. These relationships
remained significant after adjustment for other confounding factors that affect cancer survivor
QOL.
Given the increasing number of CRC survivors and their many reported health concerns
[3], improving the QOL of CRC survivors is considered a very important issue. However, it is
very difficult to predict the QOL of each cancer survivor because of the lack of valuable biolog-
ical predictive markers. Because immune system alterations and increased chronic inflamma-
tion is known to affect CRC-related symptoms, including fatigue, loss of appetite and poor
performance [13–15], pro-inflammatory cytokines have long been considered as viable marker
candidates for cancer-related symptoms. However, the modulatory role of adipokines on
inflammatory cytokines and immunologic responses and their effects on QOL remain
unknown. To our knowledge, this is the first study to investigate the relationship between
CRC-related QOL and serum chemerin levels.
Although the precise mechanism of the relationship between CRC-related QOL and che-
merin is still unknown, we suggest the following possible mechanism. Chemerin is an agonist
of the orphan G protein-coupled receptor chemokine-like receptor 1(CMKLR1, ChemR23),
which is abundantly expressed on antigen-presenting cells (APCs), including plasma dendritic
cells, natural killer cells, and macrophages [9–11, 16]. Chemerin induces the initiation of the
innate immune response and inflammatory processes by attracting these APCs [16]. Recent
studies have demonstrated a positive association between chemerin and several pro-inflamma-
tory cytokines, including interleukin 6 (IL-6), IL-8, and tumour necrosis factor (TNF)-alpha,
which is associated with cytotoxic cell-mediated immunity [17, 18]. These cytokines are
known to modulate the psycho-neuroendocrine system that induces the chronic non-specific
Table 1. (Continued)
Variables Mean±SD or Median (25th–75th percentile)
Total FACT-F score 122.40±18.40
# Non-normally distributed data were logarithmically transformed to reduce the skewness of the distribution.
Abbreviation: SD; standard deviation, BMI; body mass index, BP; blood pressure, HDL-cholesterol; high
density lipoprotein cholesterol, WBC count; white blood cell count, Hs-CRP; high sensitive c-reactive
protein, GGT; gamma glutamyl transpeptidase, FACT; Functional Assessment of Cancer Therapy.
https://doi.org/10.1371/journal.pone.0176929.t001
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behaviour symptoms termed ‘sickness behaviour’ [19]. Therefore, the pro-inflammatory and
immune-modulating properties of chemerin may influence CRC survivor QOL, including
fatigue and general symptoms.
Interestingly, we found that chemerin levels were significantly associated with CRC-related
QOL as well as general QOL and fatigue-related QOL symptoms. The CRC-related QOL ques-
tionnaires are mainly about bowel symptoms including bloating, loose stool, and abdominal
pain. Although various factors, including surgical bowel resection [20] and alteration of gut
microbial environment [21] collectively contribute to the development of chronic bowel symp-
toms in CRC survivors, it is hard to predict their occurrence and prognosis. Chemerin is
known to be elevated in the inflammatory bowel diseases, including ulcerative colitis and
Crohn’s disease [22]. Although is mainly released from adipose tissue [23], it is also synthe-
sized by foetal intestinal epithelial cells [24] and is considered to promote inflammatory pro-
cess, as well as disturb immune response that result in the chronic inflammatory bowel disease
[22, 25]. Therefore the pro-inflammatory and immune-modulating properties of chemerin
may also contribute to both the development of chronic bowel symptoms and decreases in
general and fatigue-related QOL in CRC survivors.
In addition, we suggest possible non-inflammatory roles of chemerin on QOL in CRC sur-
vivors. We observed a significant correlation between chemerin and hs-CRP levels. (r = 0.48,
Table 2. Correlations between cancer-related QOL scores and other clinical parameters.
Variables FACT scores
FACT-G Total FACT-C Total FACT-F
r p-value r p-value r p-value
Age (years) -0.19 0.04 -0.20 0.04 -0.17 0.08
Adiposity index
BMI (kg/m2) -0.98 0.30 -0.07 0.47 -0.10 0.32
Waist (cm) -0.14 0.12 -0.13 0.18 -0.15 0.11
Lean body mass (cm2) 0.14 0.16 0.19 0.05 0.12 0.21
Fat (%) -0.17 0.04 -0.17 0.04 -0.17 0.07
BP (mmHg)
Systolic 0.03 0.74 0.04 0.65 0.06 0.54
Diastolic 0.01 0.92 0.02 0.81 0.05 0.64
Fasting glucose (mg/dL) 0.07 0.49 0.06 0.54 0.11 0.23
Fasting insulin (μIU/mL)# -0.17 0.06 -0.14 0.14 -0.16 0.09
HOMA-IR# -0.14 0.14 -0.12 0.22 -0.12 0.22
Lipid profile (mg/dL)
Total cholesterol# -0.06 0.55 -0.04 0.71 -0.03 0.77
Triglyceride# -0.22 0.02 -0.22 0.02 -0.22 0.02
HDL-cholesterol# 0.11 0.24 0.12 0.20 0.13 0.17
WBC count 0.05 0.61 0.03 0.74 0.04 0.71
Hs-CRP -0.22 0.02 -0.23 0.02 -0.23 0.01
GGT -0.08 0.39 -0.02 0.84 -0.09 0.35
Chemerin -0.29 <0.01 -0.29 <0.01 -0.31 <0.01
Intervals after treatment completion (day) 0.02 0.83 0.03 0.75 0.04 0.69
Coefficient r and p values were calculated by Pearson’s correlation test
# Non-normally distributed data were logarithmically transformed to reduce the skewness of the distribution.
Abbreviation: BMI; body mass index, BP; blood pressure, HDL-cholesterol; high density lipoprotein cholesterol, WBC count; white blood cell count, Hs-
CRP; high sensitive c-reactive protein, GGT; gamma glutamyl transpeptidase
https://doi.org/10.1371/journal.pone.0176929.t002
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p<0.01) However, in a stepwise multivariate linear analysis, chemerin was independently asso-
ciated with FACT-G, FACT-C, and FACT-F scores even after adjusting for hs-CRP level. This
suggests that chemerin may have an independent role in the decline of quality of life in cancer
survivors apart from its role in mediating inflammatory markers. Previously, Dranse et al.[26]
have been reported higher proportions of Akkermansia and Prevotella bacteria in a wild type
mouse compared with a chemerin knock out mouse. Both these bacteria are known to be
increased in the gut of patients with irritable bowel syndrome [27, 28]. Additionally, previous
studies also have demonstrated the antimicrobial activity of chemerin[29, 30]. These results
suggest a possible role of chemerin in themodulation of the gut microbial community. Alter-
ations of the gut bacterial community have been reported after bowel resection surgery in
CRC patients[21] and are known to be related to various bowel symptoms that affect the qual-
ity of life in patients[3, 31]. Therefore, although we could not elucidate the precise mechanism
underlying the role of chemerin in dysbiosis in the gut bacterial community, chemerin may be
associated with CRC related QOL due to its modulatory effect on gut bacterial communities.
Further studies that investigate the relationship among the serum chemerin, distribution in
the gutbacterial community and quality of life in CRC survivors should be performed in the
future.
Fig 1. Relationships between serum chemerin level and FACT scores (FACT-G, FACT-C, and FACT-F). r: Pearson’s partial correlation coefficient (r = 0,
no linear relationship; r = 1 or -1, perfect linear relationship). X-axis values are based on calculated residuals from regressing serum chemerin levels on
covariates* including age, sex, smoking, alcohol, fat %, insulin, and triglycerides (a, c) and covariates# including age, sex, smoking, alcohol, fat %, lean body
mass and triglycerides (b). Y-axis values are based on calculated residuals from regressing FACT scores on covariates* including age, sex, smoking, alcohol,
fat %, insulin, and triglycerides (a, c) and covariates# including age, sex, smoking, alcohol, fat %, lean body mass, and triglycerides (b).
https://doi.org/10.1371/journal.pone.0176929.g001
Table 3. Enter method multiple linear regression analyses of serum chemerin, other clinical variables, and FACT scores.
Enter method Stepwise method
FACT-G Total
FACT-C
Total FACT-F FACT-G Total FACT-C Total FACT-F
β (SE) p-value β (SE) p-value β (SE) p-value β (SE) p-value β (SE) p-value β (SE) p-value
Age -0.20
(0.16)
0.21 -0.26
(0.20)
0.20 -0.16
(0.22)
0.47
Sex -4.96
(3.74)
0.19 -7.32
(6.94)
0.29 -6.05
(5.15)
0.24
Smoking -1.13
(3.59)
0.75 -0.84
(4.32)
0.85 -3.58
(4.95)
0.47
Alcohol 2.45
(3.42)
0.48 2.89
(4.10)
0.48 6.44
(4.71)
0.18
Fat (%) -0.08
(0.26)
0.75 -0.06
(0.29)
0.84 -0.05
(0.35)
0.89
Lean body mass
(kg)
2.92
(4.35)
0.84
Triglyceride (mg/
dL)
-2.21
(3.18)
0.49 -2.91
(3.52)
0.41 -2.23
(4.39)
0.61
Insulin (mU/ml) -1.53
(2.83)
0.59 -1.42
(3.89)
0.72
Chemerin (ng/mL) -0.12
(0.05)
0.02 -0.14
(0.06)
0.02 -0.20
(0.07)
<0.01 -0.15
(0.05)
<0.01 -0.19
(0.06)
<0.01 -0.23
(0.07)
<0.01
Variables included in the stepwise model for FACT-C scores were age, sex, BMI, alcohol consumption, smoking, marriage, cancer stage, treatment
modality, cancer location, intervals after treatment completion, lean body mass, systolic BP, total cholesterol, HDL-cholesterol, triglycerides, fasting
glucose, insulin, GGT, hs-CRP, and chemerin levels.
r2 = 0.29 for FACT-G scores, r2 = 0.31 for FACT-C scores, r2 = 0.31 for FACT-F scores in the stepwise mode
https://doi.org/10.1371/journal.pone.0176929.t003
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Despite compelling results, our study has several limitations. First, the cross-sectional study
design did not allow us to determine causality. Second the small sample size from a single hos-
pital does not allow for generalization of the data to a larger population. Third, the p values of
association between serum chemerin levels and FACT scores were<0.05, the r and r2 values
were relatively low. However based on the previous studies [32,33], the weak and low-signifi-
cance relationships found in our pilot study suggest the necessity of performing further large-
scale studies to determine the precise relationship between chemerin and quality of life in CRC
survivors. Fourth, we cannot exclude the possibility that the relationship between chemerin
and QOL in CRC survivors was mediated by unknown confounding factors. Additionally, we
did not measure other inflammatory markers except hs-CRP and chemerin levels. Therefore,
we could not compare chemerin’s association with FACT measures with those of other inflam-
matory markers. However, when we compared the effect sizes for chemerin and FACT scores
with the results of previous studies that investigated relationships between quality of life scores
and various inflammatory markers including interleukin (IL)-6, IL-1-b, IL-2, neoterin, and
TNF-alpha, the simple correlation coefficients between chemerin and FACT scores (r = -0.29
to -0.31) were similar to the simple correlation coefficients between other inflammatory mark-
ers and cancer-related QOL scores (e.g., IL-6 and FACT-F, r = -0.28; TNF-a and Global QOL,
r = 0.31; IL-1b and Fatigue VAS, r = 0.30; IL2 and Global QOL r = -0.27; neopterin and fatigue
levels on the LASA scales, r = 0.28)[13, 34–36]. Further studies that investigate the association
between various inflammatory markers and QOL in cancer survivors should be performed to
find the most valuable candidate for predicting cancer survivor QOL.
In conclusion, serum chemerin levels were weakly but independently associated with QOL
in Korean CRC survivors. Although it is impossible to determine causality and to assume clini-
cal consequences based on these weak relationships, we suggest the possibility that chemerin
may be considered a candidate biomarker related to QOL in CRC survivors. Further prospec-
tive and experimental studies are needed to clarify the clinical significance of our findings.
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